Global Chemotherapy Induced Anemia 2013: Worldwide Industry Latest Market Share, Growth, Size, Trends, Strategy and Forecast Research Report 2013
Albany, NY (PRWEB) September 24, 2013 -- Chemotherapy Induced Anemia - Pipeline Review, H2 2013
Summary
Global Markets Directs, 'Chemotherapy Induced Anemia - Pipeline Review, H2 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Chemotherapy Induced Anemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chemotherapy Induced Anemia. Chemotherapy Induced Anemia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.
To check out the complete table of contents, visit: http://www.marketresearchreports.biz/analysis-details/chemotherapy-induced-anemia-pipeline-review-h2-2013.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Chemotherapy Induced Anemia.
- A review of the Chemotherapy Induced Anemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Chemotherapy Induced Anemia pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Chemotherapy Induced Anemia.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Chemotherapy Induced Anemia pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Click Here To Download Detail Report: http://www.marketresearchreports.biz/sample/sample/175414
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Chemotherapy Induced Anemia Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Chemotherapy Induced Anemia 8
Chemotherapy Induced Anemia Therapeutics under Development by Companies 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Discovery and Pre-Clinical Stage Products 14
Comparative Analysis 14
Chemotherapy Induced Anemia Therapeutics - Products under Development by Companies 15
Companies Involved in Chemotherapy Induced Anemia Therapeutics Development 16
Eli Lilly and Company 16
Reliance Life Sciences Pvt. Ltd. 17
3SBio Inc. 18
ProMetic Life Sciences Inc. 19
Avesthagen Limited 20
Therapure Biopharma Inc. 21
Chemotherapy Induced Anemia - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
NuPIAO - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
epoetin alfa - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
PBI-1402 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
darbepoetin alfa biosimilar - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
LY-2787106 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
PanCyte - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
epoetin - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
TBI-304 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
TP-0413 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Drug For Chemotherapy Induced Anemia - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Drug For Chemotherapy Induced Anemia - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Chemotherapy Induced Anemia Therapeutics - Drug Profile Updates 40
Chemotherapy Induced Anemia Therapeutics - Discontinued Products 42
Chemotherapy Induced Anemia Therapeutics - Dormant Products 43
Chemotherapy Induced Anemia - Product Development Milestones 44
Featured News & Press Releases 44
Jan 03, 2013: Affymax And Takeda Pharma Announce Permanent J-Code For Omontys Injection Is In Effect 44
Apr 24, 2012: SBI Pharmaceuticals Announces Obtainment of Marketing Authorization of Products Containing 5-ALA from The Kingdom of Bahrain Ministry of Health 44
Jan 31, 2012: Kyowa Hakko Kirin Withdraws Domestic Application For Additional Chemotherapy-Induced Anemia Indication For NESP 45
Oct 28, 2011: ALA Study Results Presented at the 49th Annual Meeting of Japan Society of Clinical Oncology 45
Oct 05, 2011: ALA Study Results Presented at Japanese Cancer Association, 70th Annual Meeting 45
Jul 11, 2011: 3SBio Receives SFDA Approval For High-Dose EPIAO 46
Jun 02, 2011: Acceleron And Celgene Initiate Phase II/III Study Of ACE-011 To Treat Chemotherapy-Induced Anemia In Patients With Lung Cancer 47
Mar 18, 2011: Announcement of publication of ALA research in International Immunopharmacology 48
Sep 30, 2010: Safety study for subcutaneous epoetin alfa biosimilar Binocrit/Epoetin alfa Hexal/Abseamed suspended 48
Jun 06, 2010: Alder's ALD518 Antibody Therapeutic Reduces Disease Symptoms, Anemia In Phase IIa Clinical Trial In NSCLC Patients 48
Appendix 50
Methodology 50
Coverage 50
Secondary Research 50
Primary Research 50
Expert Panel Validation 50
To buy the copy of this report, visit: http://www.marketresearchreports.biz/analysis/175414.
Contact Us 51
Disclaimer 51 List of Tables
Number of Products Under Development for Chemotherapy Induced Anemia, H2 2013 8
Products under Development for Chemotherapy Induced Anemia - Comparative Analysis, H2 2013 9
Number of Products under Development by Companies, H2 2013 10
Comparative Analysis by Late Stage Development, H2 2013 11
Comparative Analysis by Mid Clinical Stage Development, H2 2013 12
Comparative Analysis by Early Clinical Stage Development, H2 2013 13
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 14
Products under Development by Companies, H2 2013 15
Eli Lilly and Company, H2 2013 16
Reliance Life Sciences Pvt. Ltd., H2 2013 17
3SBio Inc., H2 2013 18
ProMetic Life Sciences Inc., H2 2013 19
Avesthagen Limited, H2 2013 20
Therapure Biopharma Inc., H2 2013 21
Assessment by Monotherapy Products, H2 2013 22
Assessment by Stage and Route of Administration, H2 2013 24
Assessment by Stage and Molecule Type, H2 2013 26
Chemotherapy Induced Anemia Therapeutics - Drug Profile Updates 40
Chemotherapy Induced Anemia Therapeutics - Discontinued Products 42
Chemotherapy Induced Anemia Therapeutics - Dormant Products 43 List of Figures
Number of Products under Development for Chemotherapy Induced Anemia, H2 2013 8
Products under Development for Chemotherapy Induced Anemia - Comparative Analysis, H2 2013 9
Products under Development by Companies, H2 2013 10
Late Stage Products, H2 2013 11
Mid Clinical Stage Products, H2 2013 12
Early Clinical Stage Products, H2 2013 13
Discovery and Pre-Clinical Stage Products, H2 2013 14
Assessment by Monotherapy Products, H2 2013 22
Assessment by Route of Administration, H2 2013 23
Assessment by Stage and Route of Administration, H2 2013 24
Assessment by Molecule Type, H2 2013 25
Assessment by Stage and Molecule Type, H2 2013 26
Latest Reports:
China Waste Heat Utilization Equipment Industry Report, 2013-2015: http://www.marketresearchreports.biz/analysis-details/china-waste-heat-utilization-equipment-industry-report-2013-2015
China has rich waste heat resources. Especially in steel, nonferrous, chemical, cement, building materials, oil & petrochemical, light industry, coal and other sectors, waste heat resources approximately occupy 17%-67% of the total fuel consumption, of which, recyclable waste heat resource roughly stand up 60% of the total waste heat resources. At present, China’s waste heat utilization ratio is rather low, with the figure in large steel enterprises being 30%-50%. But the waste heat utilization in other sectors is even lower. Thus, China is expected to see a huge potential to improve its waste heat utilization.
By temperature of waste heat, the waste heat utilization equipments fall into two categories: the first comes to waste heat boiler which uses medium-and high-temperature waste heat; the second refers to lithium bromide refrigerator (heat pump) and screw expander, both of which use low-temperature waste heat. Of these, waste heat boiler occupies a lion’s share in waste heat utilization equipments. In 2012, the output of waste heat boiler approximated 812 sets, totaling 39,788 steam tons.
Click Here To Download Detail Report: http://www.marketresearchreports.biz/sample/sample/175307
Technology Trends in Lubricants (Mineral, Synthetic, and Bio-based) Market for Turbine Oil, Compressor Oil, Gear Oil, Hydraulic Oil, Bearing Oil and Heat Transfer Fluid Lubricant Applications - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018: http://www.marketresearchreports.biz/analysis-details/technology-trends-in-lubricants-mineral-synthetic-and-bio-based-market-for-turbine-oil-compressor-oil-gear-oil-hydraulic-oil-bearing-oil-and-heat-transfer-fluid-lubricant-applications-global-industry-analysis-size-share-growth-trends-a
Synthetic and bio-based lubricants are the major emerging lubricant products. This study highlights and explores key technology trends of synthetic, bio-based and mineral lubricants across a wide range of applications including turbine oil, compressor oil, gear oil, hydraulic oil, heat transfer fluids and bearing oil lubricants. Some of the major qualities that differentiate between lubricants include viscosity index, water separation characteristics, thermal and oxidation stability, low volatility and low carbon formation, and anticorrosion.
This market research report, analyzes the global consumption for lubricants, estimating and forecasting the market from the consumption point of view. The lubricants market has been segmented on the basis of products, applications and geography in order to provide a holistic picture of the market. Market data for all product segments has been provided on a regional level for the period 2011 to 2018. Technology trends have been provided for applications to give an overall idea about the latest happenings in the market. A comprehensive competitive landscape including company market share analysis has also been provided in this analysis.
Click Here To Download Detail Report: http://www.marketresearchreports.biz/sample/sample/175269
About Us
MarketResearchReports.Biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.
Contact
M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-997-4948
Website: http://www.marketresearchreports.biz/
Blog: http://mresearchreports.blogspot.com
Michell Thoras, Market Research Reports, http://www.marketresearchreports.biz/, +1 (518) 618-1030, [email protected]
Share this article